Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2025-12-24 @ 11:04 PM
NCT ID:
NCT03416569
Eligibility Criteria:
Inclusion Criteria:
* Aged 21 to 55 years.
* Smoked no more that 40 cigarettes, cigars or cigarillos in lifetime.
* Smoked no cigarettes, cigars or cigarillos in the last year.
* No exposure to any nicotine-containing product in the last month.
* Normal or corrected to normal vision (at least 20/80).
Exclusion Criteria:
* Pregnant or breast-feeding.
* Drug or alcohol abuse or dependence currently or in the last 2 years.
* DSM Axis I mood, anxiety or psychotic disorder.
* Cardiovascular or cerebrovascular disease.
* Hypertension (resting systolic BP above 150 or diastolic above 95 mm Hg).
* Hypotension (resting systolic BP below 90 or diastolic below 60).
* Bradycardia (heart rate \<60 bpm).
* Impaired liver or kidney function.
* Severe asthma.
* Obstructive pulmonary disease.
* Type I diabetes.
* Use of any centrally active medications.
* Use of any cardiovascular drugs, including blood pressure medications and antiarrhythmics.
* Use of diuretic medication.
* History of or current neurological illnesses, such as stroke, seizure disorders, neurodegenerative diseases, or organic brain syndrome.
* Learning disability, mental retardation, or any other condition that impedes cognition.
* Planned eye surgery.
* Inability to perform the Rapid Visual Information Processing Task.
* Known hypersensitivity to prazosin, any quinazolines, or nicotine.
* Narcolepsy.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
21 Years
Maximum Age:
55 Years
Study:
NCT03416569
Study Brief:
Protocol Section:
NCT03416569